title: The role of vimentin intermediate filaments in the progression of lung cancer.
abstract: There is an accumulation of evidence in the literature demonstrating the integral role of vimentin intermediate filaments (IFs) in the progression of lung cancers. Vimentin IF proteins have been implicated in many aspects of cancer initiation and progression, including tumorigenesis, epithelial-to-mesenchymal transition (EMT), and the metastatic spread of cancer. Specifically, vimentin IFs have been recognized as an essential component regulating EMT, major signal transduction pathways involved in EMT and tumor progression, cell migration and invasion, the positioning and anchorage of organelles, such as mitochondria, and cell-cell and cell-substrate adhesion. In tumorgenesis, vimentin forms a complex with 14-3-3 and beclin 1 to inhibit autophagy via an AKT-dependent mechanism. Vimentin is a canonical marker of EMT, and recent evidence has shown it to be an important regulator of cellular motility. Transcriptional regulation of vimentin through hypoxia-inducible factor-1 may be a potential driver of EMT. Finally, vimentin regulates 14-3-3 complexes and controls various intracellular signaling and cell cycle control pathways by depleting the availability of free 14-3-3. There are many exciting advances in our understanding of the complex role of vimentin IFs in cancer, pointing to the key role vimentin IFs may play in tumor progression.
authors: 1 Department of Biomedical Engineering, Northwestern University, Evanston, Illinois; and.
authors: Martha E
authors: ME
authors: Kidd
authors: Dale K
authors: DK
authors: Shumaker
authors: Karen M
authors: KM
authors: Ridge
mesh_terms: D063646:Carcinogenesis / Q000378:metabolism* / Q000473:pathology*; D018450:Disease Progression; D058750:Epithelial-Mesenchymal Transition / Q000502:physiology; D006801:Humans; D007382:Intermediate Filaments / Q000378:metabolism*; D008175:Lung Neoplasms / Q000378:metabolism* / Q000473:pathology*; D014746:Vimentin / Q000378:metabolism*
chemical_list: D014746:Vimentin
references: Nucleic Acids Res. 1989 Feb 25;17(4):1619-33
references: 2922288
references: Cell. 1991 Sep 6;66(5):837-47
references: 1653647
references: Oncogene. 2011 Jan 27;30(4):457-70
references: 20856200
references: Mol Cell Biol. 1987 Nov;7(11):3908-15
references: 3431546
references: J Mol Biol. 1993 Mar 20;230(2):436-52
references: 7681879
references: Exp Cell Res. 2007 Jun 10;313(10):2050-62
references: 17512929
references: J Cell Sci. 2004 Feb 29;117(Pt 6):919-32
references: 14762106
references: Nat Rev Cancer. 2002 Jun;2(6):442-54
references: 12189386
references: Mol Biol Cell. 2009 Jun;20(12):2841-55
references: 19386766
references: Nat Cell Biol. 2008 Feb;10(2):138-48
references: 18204439
references: J Clin Invest. 2009 Jul;119(7):1763-71
references: 19587451
references: Dtsch Arztebl Int. 2009 Dec;106(49):809-18; quiz 819-20
references: 20038979
references: Nature. 1986 Feb 6-12;319(6053):463-8
references: 3453101
references: Semin Cell Dev Biol. 2011 Sep;22(7):688-95
references: 21945648
references: Proc Am Thorac Soc. 2008 Sep 15;5(7):772-7
references: 18757316
references: Biochim Biophys Acta. 2009 Dec;1796(2):293-308
references: 19683560
references: J Cell Sci. 1999 Dec;112 ( Pt 24):4615-25
references: 10574710
references: Nat Rev Mol Cell Biol. 2013 Feb;14(2):83-97
references: 23325358
references: J Cell Biol. 2010 May 3;189(3):541-56
references: 20421424
references: Cell Mol Life Sci. 2011 Sep;68(18):3033-46
references: 21637948
references: Physiol Rev. 2008 Apr;88(2):489-513
references: 18391171
references: Mol Biol Cell. 2011 Apr 15;22(8):1274-89
references: 21346197
references: Mol Biol Cell. 2009 Jun;20(11):2755-65
references: 19357195
references: Am J Respir Crit Care Med. 2009 May 15;179(10):860-8
references: 19423719
references: Clin Exp Metastasis. 2006;23(2):97-105
references: 16830222
references: Cell. 2011 Oct 14;147(2):275-92
references: 22000009
references: Histol Histopathol. 2011 May;26(5):651-62
references: 21432781
references: J Biol Chem. 1993 Jan 25;268(3):2180-8
references: 8420985
references: Eur J Immunol. 2009 Apr;39(4):1136-46
references: 19291697
references: Clin Exp Metastasis. 2009;26(1):35-49
references: 18814043
references: Exp Cell Res. 2006 May 1;312(8):1240-53
references: 16442522
references: Oncogene. 2011 Mar 24;30(12):1436-48
references: 21057535
references: J Mol Biol. 2006 Dec 15;364(5):938-44
references: 17046786
references: EMBO J. 2000 Feb 1;19(3):349-58
references: 10654934
references: Biochim Biophys Acta. 2011 Aug;1813(8):1453-64
references: 21621563
references: Biochem J. 2005 Jun 15;388(Pt 3):773-83
references: 15766329
references: Oncogene. 2004 Jan 8;23(1):298-302
references: 14647434
references: Semin Cell Dev Biol. 2011 Sep;22(7):673-80
references: 21864699
references: Biochim Biophys Acta. 2007 Mar;1773(3):427-39
references: 17270292
references: Am J Physiol Cell Physiol. 2010 Aug;299(2):C363-73
references: 20427712
references: J Biol Chem. 2000 Sep 22;275(38):29772-8
references: 10887173
references: J Invest Dermatol. 1993 Jun;100(6):729-34
references: 7684423
references: Mol Oncol. 2010 Oct;4(5):397-403
references: 20594926
references: Mol Cancer Ther. 2008 Sep;7(9):2894-903
references: 18790770
references: Annu Rev Biochem. 1994;63:345-82
references: 7979242
references: Science. 2012 Nov 16;338(6109):956-9
references: 23112296
references: FASEB J. 2011 Nov;25(11):3873-83
references: 21803859
references: Leuk Lymphoma. 2011 May;52(5):849-64
references: 21323512
references: Cancer Res. 2003 Mar 1;63(5):1138-43
references: 12615733